It could easily happen if the valuation of NGIO is right and Excellegen sales go to $250 million. Beyond those two, research news that is positive from Regentys or getting AltuCell progressing would be considerable achievement and probably boost the share price by several dollars each. Those catalysts are are not that far off compared to how long we have been here at least many of us.

Having said that, we are a 25 cent stock and someone seems to want it that way.